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Abstract. Genetic heterogeneity is recognized as a major 
contributing factor of glioblastoma resistance to clinical treat-
ment modalities and consequently low overall survival rates. 
This genetic diversity results in variations in protein expres-
sion, both intratumorally and between individual glioblastoma 
patients. In this regard, the spectraplakin protein, microtubule 
actin cross-linking factor 1 (MACF1), was examined in glio-
blastoma. An expression analysis of MACF1 in various types 
of brain tumor tissue revealed that MACF1 was predominately 
present in grade III-IV astroctyomas and grade IV glioblas-
toma, but not in normal brain tissue, normal human astrocytes 
and lower grade brain tumors. Subsequent genetic inhibition 
experiments showed that suppression of MACF1 selectively 
inhibited glioblastoma cell proliferation and migration in cell 
lines established from patient derived xenograft mouse models 
and immortalized glioblastoma cell lines that were associated 
with downregulation of the Wnt-signaling mediators, Axin1 
and β-catenin. Additionally, concomitant MACF1 silencing 
with the chemotherapeutic agent temozolomide (TMZ) used 
for the clinical treatment of glioblastomas cooperatively 
reduced the proliferative capacity of glioblastoma cells. In 
conclusion, the present study represents the first investigation 
on the functional role of MACF1 in tumor cell biology, as well 
as demonstrates its potential as a unique biomarker that can be 
targeted synergistically with TMZ as part of a combinatorial 
therapeutic approach for the treatment of genetically multi-
farious glioblastomas.
Introduction
Glioblastomas have an age adjusted incidence of 3 per 100,000 
persons per year in the United States and comprise approxi-
mately 45% of all gliomas with a relative survival rate of 5%, 
5-years post-diagnosis (1), which can be attributed in part to 
high rates of tumor recurrence. A major contributor to the 
low survival rates of patients with these cancers is the incred-
ibly complex glioblastoma genome, which has a vast number 
of uncharacterized expressed genetic abnormalities that 
contribute to intra- and intertumor variation that negatively 
impact therapeutic response and patient outcomes (2). The 
poor prognosis of brain tumor patients, particularly those with 
glioblastoma, can be attributed in part to the limited number 
of aberrantly expressed factors used clinically as diagnostic 
and prognostic indicators. These have included genetic muta-
tions, deletions, amplifications, and epigenetic changes in 
isocitrate dehydrogenase (IDH), EGFR and O6-methylguanine 
DNA methyltransferase (MGMT) (3-8). In the present study, 
we investigated microtubule actin cross-linking factor 1 
(MACF1), which functions to crosslink microtubules and 
actin filaments, for its role in tumor cell biology and as a novel 
target in glioblastoma. Although to date MACF1 has received 
little consideration in tumor cell biology and as a target in 
human cancers, its function as a cytoskeleton integrator has 
been shown to be involved in organization of the cytoskel-
eton (9), tissue repair (10) and vertebrate development (11). 
These studies provided correlative evidence that MACF1 is 
involved in processes such as metastatic invasion in which 
cytoskeleton organization is a key element that contributes 
to tumor progression in various human cancers, as well as 
cellular and physiological processes such as tissue repair 
when dysregulated in normal tissue can lead to tumorigenesis. 
Additionally, studies by Sjöblom et al (12) identified MACF1 
as a candidate breast cancer gene in a mutational analysis 
study, while Misquitta-Ali et al (13) detected alternatively 
spliced exons in MACF1 transcripts from lung cancer patients 
providing further evidence, albeit circumstantial, that MACF1 
plays a role in human cancer. In the present study, we demon-
strated that genetic inhibition of MACF1, which we found to 
be expressed at high levels in glioblastoma relative to normal 
brain tissue, had anti-tumorigenic effects on glioblastoma 
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cell behavior and a synergistic effect with temozolomide, an 
alkylating agent used clinically to treat this disease. To the 
best of our knowledge, this is the first investigation to evaluate 
the functional role of MACF1 in human cancers and as a target 
that enhances the efficacy of therapeutic treatment modalities.
Materials and methods
Cells culture conditions and reagents. U251 human glioblas-
toma cells were purchased from Sigma-Aldrich (St. Louis, 
MO, USA) and the U87 and A172 human glioblastoma cells 
were from the American Type Culture Collection (ATCC; 
Manassas, VA, USA). Normal human astrocytes were obtained 
from Sciencell Research Laboratories (Carlsbad, CA, USA). 
All cell lines were maintained in Dulbecco's modified Eagle's 
medium-DMEM (Invitrogen, Carlsbad, CA, USA) containing 
10% fetal bovine serum (FBS; Invitrogen), 2 mM L-glutamine 
(Invitrogen), 100 nM MEM non-essential amino acids 
(Invitrogen) and penicillin-streptomycin (Invitrogen) at 37˚C 
and 5% CO2. Accell SMARTpool siRNAs targeting MACF1 
were purchased from GE Dharmacon (Chicago, IL, USA). 
Temozolomide was purchased from Sigma-Aldrich. GBM76 
patient derived xenograft cells were established at the Mayo 
Clinic (Rochester, MN, USA) (14), while primary xenograft 
lines T4105 and T4302 were provided by Jeremy Rich from 
the Cleveland Clinic (Cleveland, OH, USA). Patient derived 
xenograft cell lines (GBM76, T4105 and T4302) were serially 
passaged as subcutaneous tumors in immunocompromised 
mice and maintained as ex vivo cultures in neurobasal medium 
supplemented with B27 serum substitute, 20 ng/ml EGF and 
20 ng/ml bFGF (Life Technologies, Carlsbad, CA, USA).
Immunohistochemistry. Brain tumor tissue arrays were 
purchased from US Biomax, Inc., (Rockville, MD, USA) 
to evaluate MACF1 expression. Each slide contained the 
following number and array of brain tumor tissue sections 
provided by the supplier: 10 grade (I-II) astrocytomas, 10 
grade (III-IV) astrocytomas, 33 grade (IV) glioblastomas, 
3 oligoastrocytomas, 6 grade (I-II) oligodendrogliomas, 
3 medulloblastomas, 3 anaplastic oligodendrogliomas, 4 
ependymomas and cancer adjacent normal tissue from 5 
brains. Paraffin-embedded tissue sections were dewaxed in 
xylene for 5 min, rehydrated in 100% ethanol, 95% ethanol 
and water. Next tissue was fixed with 100% methanol at 
-20˚C for 15 min and washed three times with phosphate-
buffered saline (PBS). Detection of MACF1 was conducted 
using the ImmunoCruz rabbit ABC Staining system (Santa 
Cruz Biotechnology, Dallas, TX, USA). Tissue sections were 
blocked for 1 h in 1.5% normal horse serum in PBS at room 
temperature, permeabilized with 0.05% Triton-X in PBS for 
10 min, incubated overnight at 4˚C with a polyclonal MACF1 
antibody (Santa Cruz Biotechnology) and rinsed three times 
with PBS. Subsequently, sections were incubated with a 
biotinylated secondary antibody for 3 h at room temperature 
and washed in PBS three times 5 min each. Sections were 
then incubated with an avidin-biotinylated HRP complex 
for 30 min, rinsed again three times with PBS and MACF1 
protein visualized as diaminobenzidine (DAB) positive 
cells in tissue sections with a peroxidase substrate solution 
containing substrate buffer, DAB and peroxidase substrate 
according to the manufacturer's instructions. Images were 
then taken with a Leica DM4000 microscope and QImaging 
system (Leica Microsystems, Inc., Buffalo Grove, IL, USA).
MACF1 silencing. For silencing experiments 3.5x104 U251, 
A172, or patient derived xenograft cells were plated in 6-well 
plates, grown for two days to 70% confluency, and treated with 
1 µM non-targeting control siRNAs, 1 µM siRNAs targeting 
MACF1 (GE Dharmacon), or shRNAs targeting MACF1 
from the MISSION shRNA Library (TRCN0000294117 and 
TRCN0000294123; Sigma-Aldrich) and allowed to incubate 
for 6 days in Accell media for siRNAs or neurobasal medium 
for shRNAs. MACF1 expression was subsequently examined 
in control and MACF1 silenced cells using immunoblotting 
procedures.
Cell proliferation assay. To assess the effects of silencing 
MACF1 on cell proliferation and viability, cells were treated 
with 1 µM of non-targeting control siRNAs or siRNAs 
targeting MACF1 (GE Dharmacon) and allowed to incubate 
for 6 days in 6-well plates as described above. At the end of 
the 6-day incubation period 1.5x104 cells treated with control 
or siRNAs targeting MACF1 were replated in 12-well plates 
and allowed to incubate in the absence of siRNAs for 2, 4, 
and 6 days in DMEM media (Invitrogen) containing 10% FBS 
(Invitrogen). At the end of each time-point cells were evaluated 
using the crystal violet cell proliferation assay, one of three 
standard assays that can be used to evaluate cytotoxicity and/or 
cell viability that provide a measure of cell proliferation (15). 
Tissue culture medium was removed and the cell monolayer 
was fixed with 100% methanol for 5 min and stained with 0.5% 
crystal violet in 25% methanol for 10 min. Cells were then 
washed three times 5 min each with distilled water to remove 
excess dye and allowed to dry overnight at room temperature. 
The incorporated dye was then solubilized in 0.1 M sodium 
citrate (Sigma-Aldrich) in 50% ethanol. Next, 100 µl of experi-
mental samples were transferred to 96-well plates and optical 
densities read at 540 nm using a xMark microplate absorbance 
spectrophotometer (Bio-Rad Laboratories, Hercules, CA, 
USA). For combinatorial experiments glioblastoma cells were 
also first treated for 6 days with control non-targeting siRNAs 
or siRNAs targeting MACF1, as previously described. Next 
2.5x104 siRNA treated cells were replated in 12-well plates in 
the absence of siRNAs. Controls and conditions for combinato-
rial experiments included: replated siRNA treated cells grown 
for 72 h, replated siRNA treated cells exposed to TMZ or 
DMSO 6 h after replating and allowed to incubate in TMZ or 
DMSO for 72 h, and non-treated siRNA cells exposed to TMZ 
or DMSO 6 h after plating and grown for 72 h in the presence 
of TMZ or DMSO. DMSO is a solvent used to dissolve drugs 
and was used as a vehicle control to discern the effects of TMZ 
from the drug solvent. To evaluate the combinatorial effects 
of silencing MACF1 and TMZ treatment on cell proliferation 
and viability the cell proliferation assay, as described above, 
was also used at the end of the 72-h incubation time-point.
Cell motility. Motility assays were conducted according to the 
manufacturer's instructions (Cell Biolabs, Inc., San Diego, CA, 
USA). MACF1 silencing was performed as described above. 
Cell suspensions containing 0.5-1.0x106 cells/ml of siRNA 
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control or siRNA targeted MACF1 treated cells were prepared 
in serum-free media, while 500 µl of media containing 10% 
FBS was added to the lower chamber of the migration plate. 
A total of 300 µl of siRNA treated cell suspensions were then 
added to the inside of each insert and were allowed to incubate 
for 24 h at 37˚C and 5% CO2. Subsequently, non-migratory 
cells were removed from plate inserts (per manufacturer's 
instructions), migratory cells were stained with crystal violet 
and the dye eluted as described above. Optical densities were 
read at 595 nm using a xMark microplate absorbance spectro-
photometer (Bio-Rad Laboratories) and statistical evaluation 
of the data was performed as described below.
Western blotting. Cells treated for 6 days with control siRNAs 
or siRNAs targeting MACF1 were rinsed with PBS and lysed 
with CelLytic M Cell lysis reagent (Sigma-Aldrich). Protein 
concentrations were subsequently determined using the 
Bradford method. Proteins were separated by SDS-PAGE 
in 4-15% polyacrylamide gels (Bio-Rad Laboratories), then 
transferred to nitrocellulose membranes. For immunoblotting, 
nitrocellulose membranes were incubated with MACF1 (Santa 
Cruz Biotechnology), Axin1 (Cell Signaling Technology, 
Danvers, MA, USA), phospho β-catenin (Cell Signaling 
Technology) and GAPDH (Cell Signaling Technology) 
antibodies recognizing target proteins overnight at 4˚C. The 
membranes were then incubated with an HRP-conjugated 
secondary antibody for 1 h at room temperature, analyzed 
by enhanced chemiluminescence (ECL) detection system 
(Thermo Fisher Scientific, Nashville, TN, USA) and visual-
ized using a UVP BioSpectrum imaging system (UVP, LLC, 
Upland, CA, USA). Densitometry analysis was performed 
with the Image Studio Lite software (LI-COR Biosciences, 
Lincoln, NE, USA).
Statistical analysis. Cell proliferation, migration, time-course 
and combinatorial experiments were each performed at least 
three times with duplicate or triplicate samples. Means were 
determined by averaging duplicate or triplicate samples within 
each independent experiment. Students t-tests and ANOVA 
analysis were used to evaluate the significance between the 
experimental conditions with a P-value of 0.05 and 0.01, 
respectively.
Results
Differential expression of MACF1 in brain tumors. Identi-
fication and expression profiling of tumor specific biomarkers 
are essential for clinical diagnostic and prognostic purposes. 
Using immunohistochemistry procedures we examined 
MACF1 expression in low and high grade brain tumors. Our 
data showed that MACF1 was expressed diffusely and at the 
periphery in 40% of grade IV glioblastoma tissue sections as 
compared to its absence in normal brain tissue (Fig. 1A-C). 
In contrast to its expression in glioblastoma, MACF1 was 
absent in lower grade brain tumors (oligodendroglioma and 
medulloblastoma) and normal brain tissue (Fig. 1D-F), but 
present in grade II-IV astrocytomas as compared to normal 
brain tissue (Fig. 2). Complementing data observed in human 
tissue, immunoblotting procedures of MACF1 in glioblastoma 
cell lines also displayed significantly higher levels of MACF1 
as compared to its expression in normal human astrocyte cells 
(Fig. 2). Collectively, these data provide evidence that MACF1 
is predominately expressed in high grade malignant brain 
tumors and suggest that it is a potential biomarker and target 
in these cancers.
Anti-tumorigenic effects of suppressing MACF1 in glioblas-
toma. MACF1 to date has received no consideration as a 
target in cancer and associated cell behavior. Using siRNAs to 
inhibit MACF1 function we assessed the effects of downregu-
lating MACF1 expression on glioblastoma cell proliferation 
and migration. Western blot experiments demonstrated the 
Figure 1. MACF1 expression in brain tumors and normal brain tissue. MACF1 was robustly expressed in glioblastoma (A-C) but not detected in oligoden-
droglioma (D), medulloblastoma (E), or normal brain tissue (F). MACF1 protein is labeled as black diaminobenzidine (DAB) positive cells. Displayed is an 
immunohistochemistry labeling experiment representative of three independent experiments that showed similar results (total magnification, x200).
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efficacy of the siRNAs in silencing MACF1 in U251 and 
A172 glioblastoma cells. Our data also revealed that silencing 
MACF1 in U251 glioblastoma cells caused a 45 and 37% 
decrease in cell viability 4 and 6 days post-treatment, respec-
tively (Fig. 3). However, suppressing MACF1 expression did 
not reduce A172 glioblastoma cell viability (Fig. 3). We further 
evaluated the effects of inhibiting MACF1 in patient derived 
xenograft cell lines (Fig. 4). Time course analysis displayed 
that shRNAs targeting MACF1 significantly inhibited the 
growth of T4105 and T4302 xenograft cell lines, while SF295 
and GBM76 cells were decreased to a much lesser extent 
Figure 2. Western blot analysis of MACF1 expression in astrocytomas 
and glioblastoma cell lines. Astrocytoma tissue taken from tumor patients 
(top panel) and glioblastoma cell lines (bottom panel) displayed increased 
MACF1 protein levels as compared to normal human astrocytes (NHA) and 
normal brain tissue. Immunoblots are representative of at least four experi-
ments that showed equivalent results. Actin was used as a loading control to 
assess that lanes were loaded with the same amount of total proteins.
Figure 3. Proliferative response of glioblastoma cells to MACF1 inhibition. 
(A) Western blot analysis of U251 and A172 cells treated for six days with 
MACF1 siRNAs nearly abolished MACF1 expression in U251 and A172 cells. 
(B) Bar graphs show that reduction in MACF1 levels was accompanied with 
a significant decrease in the proliferative capacity of U251 cells (*P<0.05 as 
determined by the Student's t-test; error bars, SE) but not A172 cells. Data 
shown are representative of at least three independent experiments performed 
in duplicate. Black bars, control siRNA treated cells; white bars, MACF1 
siRNA treated cells.
Figure 4. Downregulation of MACF1 impairs proliferation of patient derived 
xenograft cell lines. Time-course analysis showed that inhibition of MACF1 
with shRNAs decreased the proliferative capacity of patient derived glioblas-
toma cell lines established in xenograft mouse models. 
Figure 5. Effects of silencing MACF1 on glioblastoma cell migration. 
Downregulation of MACF1 significantly impeded cell migration of U251 
cells (top panel), but not A172 cells (bottom panel). Bar graphs displayed are 
representative of three independent experiments performed in duplicate that 
showed similar results. Black bars, control siRNA treated cells; white bars, 
MACF1 siRNA treated cells (*P<0.05 as determined by the Student's t-test; 
error bars, SE).
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(Fig. 4). Consistent with the anti-proliferative effects of down-
regulating MACF1 protein levels in U251 cells, repression of 
MACF1 also significantly reduced U251 cell migration but not 
A172 cells (Fig. 5). Furthermore, because MACF1 has been 
implicated as a modulatory signaling contributor of the Wnt 
signaling pathway (16,17), whose dysregulation is well known 
to be involved in tumor proliferation and migratory invasion in 
a number of human cancers (18-20) including malignant brain 
tumors (21-24) we evaluated the impact of silencing MACF1 
on Wnt-signaling proteins. Our data showed that downregula-
tion of MACF1 protein levels was accompanied by decreased 
Axin1 and activated form of β-catenin protein levels (Fig. 6), 
suggesting that reduction of these Wnt-signaling mediators 
contribute to the anti-tumorigenic response of impairing 
MACF1 in glioblastoma.
Synergistic effects of MACF1 inhibition and TMZ. Chemo-
therapeutic agents used to treat glioblastoma have been 
minimally effective in part as a consequence of expressed 
genetic aberrations that contribute to intrinsic and acquired 
tumor resistance (25). We subsequently performed combinato-
rial studies to test the effectiveness of downregulating MACF1 
along with the effects of the alkylating agent, temozolomide 
(TMZ) in glioblastoma cells. For combinatorial experi-
ments, glioblastoma cells were treated with siRNAs targeting 
MACF1 and 100 µM TMZ and compared to cells treated with 
TMZ alone or cells treated with siRNAs targeting MACF1 
alone. ANOVA analysis (P<0.01) of data from cell prolifera-
tion assays revealed that the combination of MACF1 and TMZ 
treatment had the strongest effect on decreasing glioblastoma 
cell viability when compared to other treatment conditions 
and controls. Additionally, concurrent treatment of U251 
glioblastoma cells with MACF1 targeting siRNAs and TMZ 
exhibited a 1.5- and 2-fold cell viability decrease as compared 
to cells treated with either MACF1 siRNAs or TMZ alone 
(Fig. 7). A similar response was observed in A172 cells, which 
displayed a 1.32- and 1.48-fold decrease in cell viability when 
treated concurrently with TMZ and siRNAs targeting MACF1 
as compared to treatment with either of these conditions 
alone. We further examined by western blotting the effects of 
TMZ on the expression levels of MACF1 and Axin1 in U251 
cells treated for 3 h with 100 µM TMZ. These experiments 
showed that TMZ increased the protein levels of MACF1 
and the Wnt-cytoplasmic complex protein, Axin1 in U251 
cells (Fig. 8), further supporting the combinatorial approach 
and need to inhibit MACF1 in glioblastoma cells treated with 
TMZ to achieve a synergistic effect.
Discussion
The scope of genetic abnormalities in the glioblastoma genome 
was recently supported in a broad genome sequence study that 
revealed 512 mutated genes in U87 glioblastoma cells, the most 
commonly studied glioblastoma in vitro cell line model (26). 
This study provided perspective on the instability of the glio-
blastoma genome and on the scope of functional studies that 
must be undertaken to decipher the roles of uncharacterized 
genetic aberrations and their protein products in glioblastoma. 
Cytoskeletal proteins play a key role in motility, inva-
sion and proliferation (27). In this study we investigated the 
Figure 6. Suppression of MACF1 reduced Axin1 and β-catenin expression. 
Inhibition of MACF1 with siRNAs downregulated Axin1 and β-catenin 
protein levels in U251 glioblastoma cells. (A) Western blot experiments and 
(B) densitometric analysis. Data shown are representative of at least three 
independent experiments that displayed comparative results. 
Figure 7. MACF1 repression with concurrent TMZ treatment. Glioblastoma 
cells with silenced MACF1 treated with 100 µM TMZ led to a decrease 
in glioblastoma cell proliferation compared to the treatment with vehicle 
DMSO, control siRNAs, TMZ, or MACF1 siRNA alone as determined by 
ANOVA analysis and Sidak's post hoc multiple comparisons test (*P<0.05, 
**P<0.01, ***P<0.001).
Figure 8. Induction of MACF1 and Axin1 by TMZ. Densitometric analysis of 
immunoblot showed that TMZ upregulated MACF1 and Axin1 protein levels 
in U251 glioblastoma cells. Data shown are representative of at least three 
independent experiments that displayed comparative results.
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cytoskeletal spectraplakin protein, MACF1, as a potential 
diagnostic and prognostic marker and have evaluated its 
potential to be a target for glioblastoma therapy. Our findings 
that MACF1 was predominantly expressed in glioblastoma 
but absent in normal brain tissue and lower grade brain tumors 
suggest that MACF1 is a potential tumor-specific marker of 
this grade IV brain tumor. Taken together, our finding that 
MACF1 downregulation with RNA interference reduces the 
proliferation and migration of glioblastoma cells, indicates 
that MACF1 expression positively influences the proliferation 
and migration of glioblastoma cells. A similar conclusion was 
reached in studies by Hu et al (28) and Wu et al (17) which 
demonstrated that genetic inhibition and absence of MACF1 
causes a cell cycle arrest associated decrease in osteoblastic 
cell proliferation and impaired keratinocyte migration, respec-
tively. It should also be mentioned that the role of cell death 
was not examined as an underlying cause of the decrease in 
glioblastoma cell proliferation and viability in response to 
negatively regulating MACF1 function in this study, which is 
complicated by the established evasiveness of glioblastomas 
from apoptotic cell death in response to various treatment 
modalities. In this regard forthcoming studies will examine 
whether inhibition of MACF1 promotes apoptotic cell death or 
autophagy, the preferred mode of cell death in glioblastomas.
Along with its influence on cell behavior, an early investiga-
tion by Chen et al (16) also revealed that MACF1 was involved 
in the Wnt-signaling axis and showed that downregulation of 
MACF1 decreased nuclear β-catenin and led to an inhibition 
of Wnt induced β-catenin-dependent transcriptional activation 
in P19 and Rat-1 cells. Paralleling these observations, our 
results demonstrate that the scaffolding protein Axin1 and 
the transcriptional activator β-catenin of the Wnt signaling 
pathway are decreased in cells with suppressed MACF1. 
These data indicate that MACF1 contributes to the regulation 
of glioblastoma cell proliferation and migration by intervening 
in the Wnt-signaling pathway.
Our results also show that although MACF1 is expressed 
at similar levels in U251 and A172 glioblastoma cells, its 
silencing impedes motility and proliferation in U251, but 
not A172 cells. This could be due to heterogeneous genetic 
alterations between these two cell lines, such as p53 which 
is mutated in U251 and wild-type in A172 or differential 
expression of MACF1 isoforms. In support of this hypothesis, 
glioblastoma cell lines have been shown to be disparate in their 
genetic alterations (29). In addition, several MACF1 isoforms 
with different 5'UTRs and variations in the N-terminal 
actin-binding domain region have been described (30), but 
their functions have yet to be deciphered. Furthermore, it 
has been demonstrated that isoform specific silencing of the 
actin-binding protein α-actinin in glioblastoma cells has been 
shown to lead to different cellular outcomes (31), raising the 
possibility that differential expression of MACF1 isoforms 
may affect glioblastoma cell behavior. To this end, future 
studies will investigate the inhibitory effects of silencing 
different MACF1 isoforms that could impair glioblastoma 
cell proliferation and migration, particularly in A172 cells that 
were impervious to MACF1 inhibition in this study.
Clinically, TMZ is among the lead chemotherapeutic 
agents used for the treatment of nervous system cancers, 
particularly malignant brain tumors, because of its bioavail-
ability and limited toxicity (32). However, a caveat of its 
efficacy has been intrinsic and acquired resistance as a result 
in part of activating pro-survival signaling mediators (33-35). 
From a therapeutic precision medicine standpoint, our data 
show that in glioblastoma cells in which MACF1 downregu-
lation decreases proliferation and motility, reduced MACF1 
levels also enhances the anti-proliferative effect of TMZ. 
Interestingly, our results also show that TMZ induces the 
expression of MACF1 and Axin1, indicating that MACF1-Wnt 
signaling, may contribute to TMZ resistance and perpetuate 
glioblastoma cell survival. These data are in line with find-
ings that combinatorial targeted therapy approaches with 
TMZ is efficient at enhancing the progression-free survival of 
patients with genetically diverse glioblastomas (36-38). Taken 
together, our results identify MACF1 as a unique target with 
the potential to broaden combinatorial treatment paradigms in 
glioblastomas with diverse genetic profiles.
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